Testing your dermatological treatments in human skin can accelerate lead optimization and reduce the risk of clinical failure due to lack of efficacy. But how are models using human tissue established? And what is their experimental output?
In this infographic, we demonstrate how scientists at Biopta (REPROCELL) helped Pharma to accelerate the optimization of their lead Psoriasis compound using human skin models. Our researchers were able to determine the optimal concentration of the Psoriasis treatment, and confirm whether it could reduce inflammation using both induced-phenotype and diseased skin models. Read on to discover the aims and methodology behind this study.
In this infographic, we have summarized the aims, methods and findings of a study investigating the behavior of a Psoriasis treatment in human fresh tissue. Through the initial pilot study we were able to estimate the optimal concentration of the compound for use in Phase 2 which included healthy and diseased skin biopsies from Psoriasis donors.
You can find out more about our healthy, induced-phenotype, and diseases human tissue models on our website.